[go: up one dir, main page]

AP2007003869A0 - Rage fusion proteins and methods of use - Google Patents

Rage fusion proteins and methods of use

Info

Publication number
AP2007003869A0
AP2007003869A0 AP2007003869A AP2007003869A AP2007003869A0 AP 2007003869 A0 AP2007003869 A0 AP 2007003869A0 AP 2007003869 A AP2007003869 A AP 2007003869A AP 2007003869 A AP2007003869 A AP 2007003869A AP 2007003869 A0 AP2007003869 A0 AP 2007003869A0
Authority
AP
ARIPO
Prior art keywords
methods
fusion proteins
rage fusion
rage
proteins
Prior art date
Application number
AP2007003869A
Other languages
English (en)
Inventor
Adnan Mjalli
Robert Rothlein
Ye Tian
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of AP2007003869A0 publication Critical patent/AP2007003869A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
AP2007003869A 2004-08-03 2005-08-03 Rage fusion proteins and methods of use AP2007003869A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59855504P 2004-08-03 2004-08-03
PCT/US2005/027705 WO2006017647A1 (en) 2004-08-03 2005-08-03 Rage fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
AP2007003869A0 true AP2007003869A0 (en) 2007-02-28

Family

ID=35149359

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007003869A AP2007003869A0 (en) 2004-08-03 2005-08-03 Rage fusion proteins and methods of use

Country Status (23)

Country Link
US (5) US7901688B2 (no)
EP (1) EP1781700B1 (no)
JP (1) JP5188804B2 (no)
KR (1) KR101323411B1 (no)
CN (1) CN1993378A (no)
AP (1) AP2007003869A0 (no)
AU (1) AU2005271452B2 (no)
BR (1) BRPI0514052A (no)
CA (1) CA2570324C (no)
CR (1) CR20110556A (no)
EA (1) EA012082B1 (no)
EC (1) ECSP077221A (no)
ES (1) ES2473587T3 (no)
GE (1) GEP20105110B (no)
IL (1) IL180554A (no)
MA (1) MA29067B1 (no)
MX (1) MX2007001559A (no)
NO (1) NO20065949L (no)
NZ (1) NZ552128A (no)
TN (1) TNSN07037A1 (no)
UA (1) UA93356C2 (no)
WO (1) WO2006017647A1 (no)
ZA (2) ZA200700643B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7288250B2 (en) * 2003-09-11 2007-10-30 Critical Therapeutics, Inc. Monoclonal antibodies against HMGB1
GEP20105111B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and methods of use
UA93356C2 (ru) * 2004-08-03 2011-02-10 Tpahctek Фарма, Инк. Белки слияния ha ochobe rage и способы их использования
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
JP2009517404A (ja) * 2005-11-28 2009-04-30 メディミューン，エルエルシー Ｈｍｇｂ１および／またはｒａｇｅのアンタゴニストならびにその使用方法
RU2431804C2 (ru) * 2005-12-23 2011-10-20 ДжиКоудер Системз АБ Шаблон позиционирования
EA015657B1 (ru) * 2006-02-09 2011-10-31 Транстек Фарма, Инк. Слитые белки rage и способы применения
EP2021474A2 (en) * 2006-05-05 2009-02-11 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
CA3161849A1 (en) 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
AU2008265983B2 (en) 2007-06-14 2013-06-20 Galactica Pharmaceuticals, Inc. RAGE fusion proteins
WO2009054435A1 (ja) * 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. 増強されたエフェクター機能を有するポリペプチド
NL2001553C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001558C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001555C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001554C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001557C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001552C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001551C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001556C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
ES2616728T3 (es) 2008-05-23 2017-06-14 Siwa Corporation Procedimientos y composiciones para facilitar la regeneración
WO2010122460A1 (en) 2009-04-20 2010-10-28 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR20220003656A (ko) 2011-06-28 2022-01-10 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
WO2013003649A2 (en) * 2011-06-28 2013-01-03 Inhibrx Llc Wap domain fusion polypeptides and methods of use thereof
BR112015004734A2 (pt) * 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
WO2015023165A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 염증조절복합체 및 ｓｔａｔ３ 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포
EP3194439B1 (en) * 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
EP3677598B1 (en) 2016-02-19 2022-04-06 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
AU2017250301A1 (en) 2016-04-15 2018-11-15 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
CN115304669A (zh) * 2016-06-08 2022-11-08 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
JP7577447B2 (ja) * 2017-02-17 2024-11-05 デナリ セラピューティクス インコーポレイテッド 操作されたポリペプチド
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020056379A1 (en) 2018-09-14 2020-03-19 BioAge Labs, Inc. Rage fusion proteins with improved stability and ligand binding affinity and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
NZ257942A (en) 1992-10-23 1996-04-26 Immunex Corp Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
BR9607598B1 (pt) * 1995-01-18 2009-05-05 composição farmacêutica, composição tópica, composição ocular e composto.
FI119756B (fi) 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
WO1996031537A1 (en) 1995-04-05 1996-10-10 The Picower Institute For Medical Research Agents for binding to advanced glycosylation endproducts, and methods of their use
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
AU2696097A (en) 1996-04-16 1997-11-07 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
AU748768B2 (en) 1997-03-11 2002-06-13 General Hospital Corporation, The Identification of agents for use in the treatment of Alzheimer's disease
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
EP1118681A1 (en) 1998-09-29 2001-07-25 Asahi Kasei Kabushiki Kaisha Method for controlling the release of granules
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
EP1121454B1 (en) 1998-10-06 2007-11-14 The Trustees of Columbia University in the City of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US6197294B1 (en) * 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6605642B2 (en) 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
EP1307219A4 (en) 1999-08-13 2005-04-06 Univ Columbia METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF
WO2001018060A1 (fr) 1999-09-08 2001-03-15 Toray Industries, Inc. Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique
US20050170382A1 (en) 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
EP2319939A3 (en) 1999-10-21 2012-09-26 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
CA2382165A1 (en) * 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
ES2286117T3 (es) * 2000-04-14 2007-12-01 Niadyne Corporation Metodo para identificar reguladores dela formacion de proteina-age.
US20010041349A1 (en) 2000-04-17 2001-11-15 Andrew Patron Protein expression system arrays and use in biological screening
AU2001259710A1 (en) 2000-05-09 2001-11-20 Genetics Institute, Llc Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US20020104993A1 (en) * 2000-08-07 2002-08-08 Fitzgerald Eugene A. Gate technology for strained surface channel and strained buried channel MOSFET devices
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
US6563015B1 (en) 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
MXPA03002916A (es) * 2000-10-02 2004-12-03 Reddy Therapeutics Inc Metodos y composiciones para el tratamiento de enfermedades inflamatorias.
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
CA2433348A1 (en) 2000-12-29 2002-08-29 Reddy Us Therapeutics, Inc. Detection of compounds that modulate inflammatory responses
US6946277B2 (en) 2001-01-31 2005-09-20 Council Of Scientific And Industrial Research Method for enhancing cellobiase activity of termitomyces clypeatus using a glycosylation inhibitor
EP1361891A2 (en) 2001-02-19 2003-11-19 MERCK PATENT GmbH Artificial fusion proteins with reduced immunogenicity
DE10109466B4 (de) 2001-02-28 2008-01-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Mittel zur Modifikation humaner Angiogenese
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
CA2504413A1 (en) * 2001-03-22 2002-10-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and apparatus for gel-free qualitative and quantitative proteome analysis, and uses therefore
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040077601A1 (en) 2002-07-09 2004-04-22 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds
JP2006512900A (ja) 2002-08-16 2006-04-20 ワイス Ｒａｇｅ関連疾患の治療用組成物及び方法
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003285385A1 (en) 2002-12-13 2004-07-09 Licentia Ltd The transmembrane protein amigo and uses thereof
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
WO2004100890A2 (en) 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
CA2522275A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
JP2007504247A (ja) 2003-09-05 2007-03-01 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 糸球体損傷を治療するためのｒａｇｅに関連した方法および組成物
WO2005042032A1 (en) 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Methods for treating multiple sclerosis
US8003613B2 (en) 2003-11-17 2011-08-23 University Of Florida Research Foundation, Inc. Methods and compositions for inducing apoptosis
WO2005051995A2 (en) 2003-11-19 2005-06-09 Curagen Corporation Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same
GB0330079D0 (en) 2003-12-20 2004-02-04 Bioinvent Int Ab Vaccine
CN100342017C (zh) 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
PT1768677E (pt) 2004-07-02 2008-10-06 Creabilis Therapeutics Spa Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1
US20060012414A1 (en) * 2004-07-15 2006-01-19 Texas Instruments Incorporated Circuit and method for generating a polyphase clock signal and system incorporating the same
EP1814576A2 (en) 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
WO2006012415A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
UA93356C2 (ru) * 2004-08-03 2011-02-10 Tpahctek Фарма, Инк. Белки слияния ha ochobe rage и способы их использования
GEP20105111B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and methods of use
JP2008537874A (ja) 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用
US20070087406A1 (en) 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20080207499A1 (en) 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
EA015657B1 (ru) 2006-02-09 2011-10-31 Транстек Фарма, Инк. Слитые белки rage и способы применения
EP2021474A2 (en) 2006-05-05 2009-02-11 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
US20080199467A1 (en) 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
AU2008265983B2 (en) 2007-06-14 2013-06-20 Galactica Pharmaceuticals, Inc. RAGE fusion proteins

Also Published As

Publication number Publication date
CA2570324A1 (en) 2006-02-16
US20080075733A1 (en) 2008-03-27
MX2007001559A (es) 2007-04-10
AU2005271452B2 (en) 2011-11-03
US7981423B2 (en) 2011-07-19
CN1993378A (zh) 2007-07-04
EA200700404A1 (ru) 2007-06-29
ZA200906459B (en) 2010-05-26
ES2473587T3 (es) 2014-07-07
US8877192B2 (en) 2014-11-04
US20110124102A1 (en) 2011-05-26
EP1781700A1 (en) 2007-05-09
JP2008512988A (ja) 2008-05-01
TNSN07037A1 (fr) 2008-06-02
NO20065949L (no) 2007-01-16
US20110244516A1 (en) 2011-10-06
AU2005271452A1 (en) 2006-02-16
ZA200700643B (en) 2010-07-28
IL180554A0 (en) 2007-06-03
KR20070039981A (ko) 2007-04-13
EA012082B1 (ru) 2009-08-28
CA2570324C (en) 2014-07-22
WO2006017647A1 (en) 2006-02-16
GEP20105110B (en) 2010-11-10
NZ552128A (en) 2009-09-25
MA29067B1 (fr) 2007-12-03
CR20110556A (es) 2011-11-10
US20060030527A1 (en) 2006-02-09
KR101323411B1 (ko) 2013-10-30
JP5188804B2 (ja) 2013-04-24
UA93356C2 (ru) 2011-02-10
IL180554A (en) 2013-09-30
BRPI0514052A (pt) 2008-05-27
ECSP077221A (es) 2007-03-29
EP1781700B1 (en) 2014-03-19
US20120171202A1 (en) 2012-07-05
US7901688B2 (en) 2011-03-08

Similar Documents

Publication Publication Date Title
IL180554A0 (en) Rage fusion proteins and methods of use
IL180555A0 (en) Rage fusion proteins and methods of use
IL192581A0 (en) Rage fusion proteins and methods of use
IL194482A0 (en) Rage fusion proteins, formulations, and methods of use thereof
PT2650020T (pt) Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização
IL169638A0 (en) Soluble fcyr fusion proteins and methods of use thereof
IL178593A (en) Specific antibodies of fcγriib and methods for their use
IL182734A0 (en) 4-aminotetracyclines and methods of use thereof
EP1959997A4 (en) ANTAGONISTS OF HMGB1 AND / OR RAGE AND METHOD OF USE THEREOF
ZA200702634B (en) Prion protein binding materials and methods of use
EP1812030A4 (en) ANTI-ANGIOGENIC PEPTIDES AND METHODS OF USE THEREOF
IL177650A0 (en) Isoquinoline derivatives and methods of use thereof
EP2102355A4 (en) PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF
EP1786451A4 (en) ANTIANGIOGENIC PEPTIDES AND METHOD FOR THEIR USE
GB0404345D0 (en) Surgical jig and methods of use
ZA200600387B (en) Hydrolytically-resistant bornon-containing therapeutics and methods of use
HK1091894A1 (en) Prion protein binding materials and methods of use
EP1799656A4 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF USE
EP2007884A4 (en) ENZYMATIC FUSION PROTEINS AND THEIR USE
EP1794589A4 (en) PROTEIN ARRAYS AND METHOD OF USE THEREOF
EP1838288A4 (en) THERAPEUTIC MATERIALS AND METHODS
ZA200808656B (en) Enzyme fusion proteins and their use
GB0416699D0 (en) Prion protein ligands and methods of use
ZA200610232B (en) Fusion proteins comprising CD4 minimal modules and methods of use thereof
HK1082770A1 (en) Supter-antigen fusion proteins and the use thereof